Related Experiment Videos

Effects of dapagliflozin on cardiovascular risk factors

Agata Ptaszynska1, Elise Hardy, Eva Johnsson

  • 1Global Clinical Development, Metabolics, Bristol-Myers Squibb, Princeton, NJ 08540, USA.

Postgraduate Medicine
|June 11, 2013
PubMed

Insights

Dapagliflozin, a type 2 diabetes medication, improves cardiovascular risk factors like blood pressure and weight. It also reduces cardiac events, offering benefits beyond glycemic control for diabetic patients.

Area of Science:

  • Endocrinology
  • Cardiology
  • Pharmacology

Background:

  • Diabetes Mellitus (T2DM) significantly increases cardiovascular disease (CV) risk.
  • Effective management requires addressing glycemic control and other CV risk factors.
  • Sodium-glucose co-transporter 2 (SGLT2) inhibitors offer a therapeutic approach.

Purpose of the Study:

  • To evaluate the impact of dapagliflozin on cardiovascular risk factors in T2DM patients.
  • To assess the effects of dapagliflozin beyond glucose lowering.
  • To review clinical trial data on dapagliflozin's CV risk profile.

Main Methods:

  • Analysis of clinical trial data for dapagliflozin therapy in T2DM.
  • Assessment of changes in glycemic control, body weight, lipid parameters, serum uric acid, and blood pressure.
  • Meta-analysis of cardiac events in patients treated with dapagliflozin versus comparators.

Main Results:

  • Dapagliflozin improved glycemia with low hypoglycemia risk.
  • Therapy led to body weight reduction and modest blood pressure decrease.
  • Observed reductions in serum uric acid and minor lipid parameter changes.
  • Meta-analysis indicated a lower rate of cardiac events with dapagliflozin.

Conclusions:

  • Dapagliflozin demonstrates beneficial effects on multiple cardiovascular risk factors in T2DM.
  • The SGLT2 inhibitor shows promise in improving CV risk profiles.
  • Ongoing studies aim to confirm dapagliflozin's impact on definitive CV outcomes.

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...